Saudi Arabia Duodenal Ulcer Treatment Market Report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

Saudi Arabia Duodenal Ulcer Treatment Market Overview

• The Saudi Arabia Duodenal Ulcer Treatment Market is valued at USD 45 million, based on a five-year historical analysis, aligning with recent country-level revenue estimates for duodenal ulcer therapeutics. This growth is primarily driven by the increasing prevalence of duodenal ulcers associated with Helicobacter pylori infection, non-steroidal anti-inflammatory drug (NSAID) use, smoking, and changing dietary patterns, along with rising healthcare expenditure and advancements in pharmacological treatment options such as proton pump inhibitors and combination regimens. The market is also supported by a growing awareness of gastrointestinal health, national screening and early-diagnosis initiatives for digestive diseases, and broader access to specialist gastroenterology services under Saudi Arabia’s healthcare transformation programs, leading to higher demand for effective treatment solutions.
• Key cities such as Riyadh, Jeddah, and Dammam dominate the market due to their advanced healthcare infrastructure, higher concentration of tertiary hospitals, and availability of specialized gastroenterology and endoscopy services, which draw patients from across the kingdom for diagnosis and management of peptic and duodenal ulcers. These urban centers are equipped with state-of-the-art public and private hospitals and clinics, including facilities within major health clusters and academic medical centers, attracting patients seeking quality treatment for duodenal ulcers. Additionally, the presence of leading multinational pharmaceutical firms and strong local manufacturers in these regions, supported by established distribution networks and hospital pharmacy channels, further enhances market growth.
• In 2023, the Saudi Arabian government implemented the Health Insurance Law and its implementing regulations under the Council of Cooperative Health Insurance (CCHI) in updated form, mandating that all employers provide cooperative health insurance policies which must cover medically necessary outpatient and inpatient treatments, including gastrointestinal and peptic ulcer therapies, as defined in the Unified Cooperative Health Insurance Policy issued by the CCHI. This regulatory framework aims to improve access to essential medications and procedures such as endoscopy and pharmacological regimens for patients suffering from duodenal ulcers, ensuring that they receive timely and effective care with reduced out-of-pocket expenditure, particularly in the insured private-sector population.

Saudi Arabia Duodenal Ulcer Treatment Market Segmentation

By Treatment Type:

The treatment type segmentation includes various pharmacological and surgical interventions. The dominant subsegment is Proton Pump Inhibitors (PPIs), which are widely prescribed as first-line therapy in duodenal and broader peptic ulcer disease due to their effectiveness in suppressing gastric acid secretion and promoting mucosal healing. H2-Receptor Antagonists also hold a significant share, but their usage is gradually declining as PPIs have become the preferred choice in most clinical guidelines. Antibiotic regimens for H. pylori eradication, typically in combination with PPIs and other agents, are crucial for treating ulcers caused by this bacterium and for reducing recurrence rates. Antacids and Cytoprotective Agents, including agents such as sucralfate and prostaglandin analogues, are used mainly for symptomatic relief and mucosal protection, often as adjuncts rather than stand-alone curative therapies. Other pharmacological and surgical interventions, including endoscopic hemostasis and surgical procedures reserved for complicated or refractory cases, are less common but still play a role in comprehensive treatment plans, particularly in bleeding or perforated ulcers.

By Route of Administration:

The route of administration segmentation highlights the methods through which treatments are delivered to patients. Oral administration is the most prevalent route, favored for its convenience, patient adherence, and the availability of multiple PPI, H2-blocker, antacid, and antibiotic formulations in tablet, capsule, and suspension forms. Parenteral administration, while less common, is utilized in hospital settings for acute or complicated cases, such as bleeding ulcers or when rapid acid suppression is required, or when patients are unable to take medications orally. Other routes, such as localized endoscopic delivery of hemostatic agents or adjunctive therapies, are less frequently employed but may be used in specific circumstances, particularly in interventional gastroenterology. The dominance of oral administration reflects patient preferences, cost-effectiveness, and the strong evidence base supporting oral regimens for both acute management and maintenance therapy.

Saudi Arabia Duodenal Ulcer Treatment Market Competitive Landscape

The Saudi Arabia Duodenal Ulcer Treatment Market is characterized by a dynamic mix of regional and international players. Leading participants such as AstraZeneca plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc (GSK), Sanofi S.A., Johnson & Johnson (Janssen), Novartis AG, Merck & Co., Inc. (MSD), AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Eli Lilly and Company, Jamjoom Pharma, Tabuk Pharmaceuticals Manufacturing Company, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) contribute to innovation, geographic expansion, and service delivery in this space.

Saudi Arabia Duodenal Ulcer Treatment Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Duodenal Ulcers:The prevalence of duodenal ulcers in Saudi Arabia is estimated to affect approximately 1.5 million individuals annually. This rising incidence is attributed to lifestyle factors such as high-stress levels and dietary habits. According to the Saudi Ministry of Health, gastrointestinal disorders, including duodenal ulcers, account for nearly 20% of all hospital admissions, highlighting the urgent need for effective treatment options and driving market growth.
• Advancements in Treatment Technologies:The Saudi healthcare sector is witnessing significant advancements in treatment technologies for duodenal ulcers. In future, the government allocated SAR 10 billion to enhance healthcare technology, including minimally invasive surgical techniques and novel drug formulations. These innovations are expected to improve patient outcomes and reduce recovery times, thereby increasing the demand for advanced treatment options in the market.
• Rising Healthcare Expenditure:Saudi Arabia's healthcare expenditure is projected to reach SAR 200 billion in future, reflecting a 5% increase from the previous year. This rise in spending is driven by the government's commitment to improving healthcare services and infrastructure. Increased funding allows for better access to duodenal ulcer treatments, including medications and surgical interventions, thus propelling market growth and enhancing patient care.

Market Challenges

• High Cost of Advanced Treatments:The cost of advanced treatments for duodenal ulcers can be prohibitively high, with some innovative therapies exceeding SAR 15,000 per patient. This financial burden limits access for many patients, particularly in lower-income demographics. As a result, the high cost of treatment poses a significant challenge to market growth, as many individuals may opt for less effective, traditional therapies.
• Limited Access to Healthcare Facilities in Rural Areas:Approximately 30% of the Saudi population resides in rural areas, where access to specialized healthcare facilities is limited. Many rural regions lack adequate medical infrastructure, making it difficult for patients to receive timely treatment for duodenal ulcers. This disparity in healthcare access presents a significant challenge to the overall market, as it restricts the reach of advanced treatment options.

Saudi Arabia Duodenal Ulcer Treatment Market Future Outlook

The future of the duodenal ulcer treatment market in Saudi Arabia appears promising, driven by ongoing advancements in medical technology and increased healthcare investments. The integration of telemedicine is expected to enhance patient access to specialists, particularly in underserved areas. Additionally, the focus on personalized medicine will likely lead to more effective treatment protocols tailored to individual patient needs, improving overall health outcomes and patient satisfaction in the coming years.

Market Opportunities

• Expansion of Telemedicine Services:The growth of telemedicine services in Saudi Arabia presents a significant opportunity for the duodenal ulcer treatment market. With an estimated 60% of the population using smartphones, telehealth can facilitate remote consultations, improving access to specialists and enhancing patient management, particularly in rural areas.
• Development of Innovative Drug Formulations:There is a growing opportunity for pharmaceutical companies to develop innovative drug formulations targeting duodenal ulcers. With the Saudi government investing SAR 2 billion in research and development for gastrointestinal treatments, new therapies can emerge, potentially improving efficacy and patient adherence to treatment regimens.